Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
David Chang's research focuses on several areas within health and medicine, with a significant emphasis on infectious diseases, non-communicable diseases, and specific patient populations. He has investigated weight gain associated with dolutegravir in the African Cohort Study and explored the intersection of HIV and SARS-CoV-2, including vaccine research and development. His work also examines non-communicable diseases in individuals living with and without HIV across four African countries, and implementation gaps for pre-exposure prophylaxis among populations vulnerable to HIV acquisition in Kenya.
Further research interests include bone health in Duchenne muscular dystrophy, a condition influenced by multiple factors beyond corticosteroid use and loss of ambulation. Chang has also published on reducing blood culture contamination and vancomycin use through the Specimen Diversion Device® in an academic medical center, and on strategies for waste reduction in orthopedic surgery. His scholarship metrics include an h-index of 46, with 397 total publications and 8,844 total citations, designating him as a highly cited researcher. He leads a research group and collaborates with other researchers, including Zain Alamarat.
Metrics
- h-index: 46
- Publications: 395
- Citations: 8,885
Selected Publications
-
Retention, blinding, and health outcomes from a rural pediatric obesity feasibility randomized control trial (2026)
-
Efforts to Enhance Recruitment and Engagement of Caregivers from Medically Underserved Communities in a Randomized Controlled Trial of a Vaccine Promotion App (2025)
-
Corrigendum to “Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children” [Vaccine 61 (2025) 127245] (2025)
-
Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children (2025)
-
A family-based behavioral group obesity randomized control feasibility trial across a clinical trials network: a focus on contact hours (2025)
-
Validation of remote anthropometric measurements in a rural randomized pediatric clinical trial in primary care settings (2024)
-
Validation of remote anthropometric measurements in a rural randomized pediatric clinical trial in primary care settings (2023)
Collaboration Network
Top Collaborators
- TREATMENT OF ASYMPTOMATIC DONOR SPECIFIC ANTIBODY AFTER HEART TRANSPLANTATION: IS IT BENEFICIAL?
- Abstract 4140454: The Outcome of Restrictive Cardiac Allograft Physiology in Severe Coronary Allograft Vasculopathy
- KIDNEY TRANSPLANT AFTER HEART TRANSPLANT IN THE FIRST YEAR LEVELS THE SURVIVAL PLAYING FIELD
- Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
Showing 5 of 9 shared publications
- TREATMENT OF ASYMPTOMATIC DONOR SPECIFIC ANTIBODY AFTER HEART TRANSPLANTATION: IS IT BENEFICIAL?
- Abstract 4140454: The Outcome of Restrictive Cardiac Allograft Physiology in Severe Coronary Allograft Vasculopathy
- KIDNEY TRANSPLANT AFTER HEART TRANSPLANT IN THE FIRST YEAR LEVELS THE SURVIVAL PLAYING FIELD
- Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
Showing 5 of 9 shared publications
- Abstract 4140454: The Outcome of Restrictive Cardiac Allograft Physiology in Severe Coronary Allograft Vasculopathy
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
- Abstract 4145247: Optimal threshold of donor-derived cell-free DNA for detection of cardiac transplant rejection: a meta-analysis
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Abstract 4145435: Diagnostic Accuracy of Non-Invasive Assessments for Detecting Cardiac Transplant Rejection: A Meta-Analysis
Showing 5 of 6 shared publications
- TREATMENT OF ASYMPTOMATIC DONOR SPECIFIC ANTIBODY AFTER HEART TRANSPLANTATION: IS IT BENEFICIAL?
- KIDNEY TRANSPLANT AFTER HEART TRANSPLANT IN THE FIRST YEAR LEVELS THE SURVIVAL PLAYING FIELD
- Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- TREATMENT OF ASYMPTOMATIC DONOR SPECIFIC ANTIBODY AFTER HEART TRANSPLANTATION: IS IT BENEFICIAL?
- Abstract 4140454: The Outcome of Restrictive Cardiac Allograft Physiology in Severe Coronary Allograft Vasculopathy
- KIDNEY TRANSPLANT AFTER HEART TRANSPLANT IN THE FIRST YEAR LEVELS THE SURVIVAL PLAYING FIELD
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
- Prognosis Of Restrictive Cardiac Allograft Physiology Following Heart Transplantation
- Weight gain during the dolutegravir transition in the African Cohort Study
- HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
- Non‐communicable diseases by age strata in people living with and without HIV in four African countries
- Pre‐exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross‐sectional analysis in two communities in western Kenya, 2021–2023
- Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
- Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Logic of High Donor Derived Cell-Free DNA and Low GEP Score After Heart Transplant Should Equal AMR, but Not So
- ATG Induction in MCS Patients with Drive Line Infections: Is It Safe?
- Abstract 4140454: The Outcome of Restrictive Cardiac Allograft Physiology in Severe Coronary Allograft Vasculopathy
- Abstract 4145247: Optimal threshold of donor-derived cell-free DNA for detection of cardiac transplant rejection: a meta-analysis
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Abstract 4145435: Diagnostic Accuracy of Non-Invasive Assessments for Detecting Cardiac Transplant Rejection: A Meta-Analysis
- Prognosis Of Restrictive Cardiac Allograft Physiology Following Heart Transplantation
- Weight gain during the dolutegravir transition in the African Cohort Study
- Non‐communicable diseases by age strata in people living with and without HIV in four African countries
- Pre‐exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross‐sectional analysis in two communities in western Kenya, 2021–2023
- Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
- Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Logic of High Donor Derived Cell-Free DNA and Low GEP Score After Heart Transplant Should Equal AMR, but Not So
- ATG Induction in MCS Patients with Drive Line Infections: Is It Safe?
- TREATMENT OF ASYMPTOMATIC DONOR SPECIFIC ANTIBODY AFTER HEART TRANSPLANTATION: IS IT BENEFICIAL?
- KIDNEY TRANSPLANT AFTER HEART TRANSPLANT IN THE FIRST YEAR LEVELS THE SURVIVAL PLAYING FIELD
- The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution
- Weight gain during the dolutegravir transition in the African Cohort Study
- Non‐communicable diseases by age strata in people living with and without HIV in four African countries
- Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
- Abstract 4145247: Optimal threshold of donor-derived cell-free DNA for detection of cardiac transplant rejection: a meta-analysis
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Abstract 4145435: Diagnostic Accuracy of Non-Invasive Assessments for Detecting Cardiac Transplant Rejection: A Meta-Analysis
- Abstract 4145247: Optimal threshold of donor-derived cell-free DNA for detection of cardiac transplant rejection: a meta-analysis
- Abstract 4145435: Diagnostic Accuracy of Non-Invasive Assessments for Detecting Cardiac Transplant Rejection: A Meta-Analysis
- Logic of High Donor Derived Cell-Free DNA and Low GEP Score After Heart Transplant Should Equal AMR, but Not So
- Abstract 4140381: Does Induction Therapy with Anti-thymocyte Globulin Decrease First-year Intimal Thickening in Patients Experiencing Ischemia-Reperfusion Injury Immediately after Heart Transplantation?
- Logic of High Donor Derived Cell-Free DNA and Low GEP Score After Heart Transplant Should Equal AMR, but Not So
- ATG Induction in MCS Patients with Drive Line Infections: Is It Safe?
Similar Researchers
Based on overlapping research topics